Ossiam Cuts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Ossiam cut its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 57.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 73,448 shares of the company's stock after selling 98,552 shares during the quarter. Eli Lilly and Company makes up approximately 1.9% of Ossiam's investment portfolio, making the stock its 23rd largest holding. Ossiam's holdings in Eli Lilly and Company were worth $56,702,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Principal Financial Group Inc. increased its stake in Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after purchasing an additional 60,306 shares in the last quarter. M&T Bank Corp increased its position in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after acquiring an additional 1,867 shares during the period. Invst LLC raised its stake in Eli Lilly and Company by 3.5% in the 3rd quarter. Invst LLC now owns 5,552 shares of the company's stock worth $4,918,000 after acquiring an additional 189 shares during the last quarter. McIlrath & Eck LLC grew its stake in Eli Lilly and Company by 3.4% during the 3rd quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock valued at $426,000 after purchasing an additional 16 shares during the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Eli Lilly and Company by 111.7% in the third quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock valued at $5,786,000 after purchasing an additional 3,446 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

LLY has been the topic of a number of recent research reports. Morgan Stanley dropped their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Guggenheim dropped their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,017.00.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Trading Down 0.3 %

Shares of LLY stock traded down $2.45 during trading on Wednesday, hitting $825.09. 1,700,761 shares of the stock traded hands, compared to its average volume of 3,423,184. The firm has a market capitalization of $782.33 billion, a P/E ratio of 70.46, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm's fifty day moving average price is $827.10 and its 200-day moving average price is $818.99.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.